α-Adrenergic Receptor Function, Arousal and Sleep: Mechanisms and Therapeutic Implications

M. Broese; D. Riemann; L. Hein; C. Nissen

doi:10.1055/s-0031-1299728

Pharmacopsychiatry, Inhaltsverzeichnis

Pharmacopsychiatry 2012; 45(06): 209-216
DOI: 10.1055/s-0031-1299728

Review

α-Adrenergic Receptor Function, Arousal and Sleep: Mechanisms and Therapeutic Implications

M. Broese

¹Department of Psychiatry and Psychotherapy, University Medical Center Freiburg, Freiburg, Germany

,

D. Riemann

¹Department of Psychiatry and Psychotherapy, University Medical Center Freiburg, Freiburg, Germany

,

L. Hein

²Institute of Clinical and Experimental Pharmacology and Toxicology, University Medical Center Freiburg, Freiburg, Germany

,

C. Nissen

¹Department of Psychiatry and Psychotherapy, University Medical Center Freiburg, Freiburg, Germany

› Institutsangaben

Abstract

Noradrenergic (NE) neurotransmission and particularly α-adrenergic receptor function has been identified as a critical component of the sleep/wake regulation in animals and humans. This work (i) provides an update on the impact of NE neurotransmission on the sleep/wake regulation, (ii) summarizes the effects of α-receptor agonists and antagonists on arousal and sleep in animals and healthy humans, and (iii) reviews the current body of evidence for the effectiveness and safety of these compounds in the treatment of clinical conditions characterized by alterations of arousal or sleep, including attention deficit and hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), borderline personality disorder and primary sleep disorders. This systematic evaluation of the potential and limitations of the effects of α-adrenergic compounds might promote novel inroads for the treatment of these highly prevalent clinical conditions.

Key words

α-receptors - norepinephrine - clonidine - prazosin - arousal - sleep

Volltext

Referenzen

References
1 Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005; 437: 1257-1263
2 Berridge CW. Noradrenergic modulation of arousal. Brain Res Rev 2008; 58: 1-17
3 Borbely AA, Achermann P. Sleep homeostasis and models of sleep regulation. J Biol Rhythms 1999; 14: 557-568
4 Saper CB, Cano G, Scammell TE. Homeostatic, circadian, and emotional regulation of sleep. J Comp Neurol 2005; 493: 92-98
5 Dijk DJ, Czeisler CA. Contribution of the circadian pacemaker and the sleep homeostat to sleep propensity, sleep structure, electroencephalographic slow waves, and sleep spindle activity in humans. J Neurosci 1995; 15: 3526-3538
6 Bjorness TE, Greene RW, Kelly CL et al. Adenosine and sleep control and function of the homeostatic sleep response by adenosine A1 receptors. Curr Neuropharmacol 2009; 7: 238-245
7 Nelson LE, Guo TZ, Lu J et al. The sedative component of anesthesia is mediated by GABA(A) receptors in an endogenous sleep pathway. Nat Neurosci 2002; 5: 979-984
8 Espana RA, Scammell TE. Sleep neurobiology from a clinical perspective. Sleep 2011; 34: 845-858
9 Sehgal A, Mignot E. Genetics of sleep and sleep disorders. Cell 2011; 146: 194-207
10 McCarley RW, Hobson JA. Neuronal excitability modulation over the sleep cycle: a structural and mathematical model. Science 1975; 189: 58-60
11 Berridge CW, Abercrombie ED. Relationship between locus coeruleus discharge rates and rates of norepinephrine release within neocortex as assessed by in vivo microdialysis. Neuroscience 1999; 93: 1263-1270
12 Berridge CW, Page ME, Valentino RJ et al. Effects of locus coeruleus inactivation on electroencephalographic activity in neocortex and hippocampus. Neuroscience 1993; 55: 381-393
13 Foote SL, Bloom FE, Aston-Jones G. Nucleus locus ceruleus: new evidence of anatomical and physiological specificity. Physiol Rev 1983; 63: 844-914
14 Espana RA, Berridge CW. Organization of noradrenergic efferents to arousal-related basal forebrain structures. J Comp Neurol 2006; 496: 668-683
15 Aston-Jones G, Bloom FE. Activity of norepinephrine-containing locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle. J Neurosci 1981; 1: 876-886
16 Shinba T, Shinozaki T, Mugishima G. Clonidine immediately after immobilization stress prevents long-lasting locomotion reduction in the rat. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 1629-1640
17 Tanaka M, Kohno Y, Tsuda A et al. Differential effects of morphine on noradrenaline release in brain regions of stressed and non-stressed rats. Brain Res 1983; 275: 105-115
18 Foote SL, Aston-Jones G, Bloom FE. Impulse activity of locus coeruleus neurons in awake rats and monkeys is a function of sensory stimulation and arousal. Proc Natl Acad Sci USA 1980; 77: 3033-3037
19 Aston-Jones G, Cohen JD. An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. Annu Rev Neurosci 2005; 28: 403-450
20 Berridge CW, Isaac SO, Espana RA. Additive wake-promoting actions of medial basal forebrain noradrenergic alpha1- and beta-receptor stimulation. Behav Neurosci 2003; 117: 350-359
21 McCormick DA, Pape HC, Williamson A. Actions of norepinephrine in the cerebral cortex and thalamus: implications for function of the central noradrenergic system. Prog Brain Res 1991; 88: 293-305
22 Jodo E, Chiang C, Aston-Jones G. Potent excitatory influence of prefrontal cortex activity on noradrenergic locus coeruleus neurons. Neuroscience 1998; 83: 63-79
23 Bylund DB, Eikenberg DC, Hieble JP et al. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 1994; 46: 121-136
24 Gilsbach R, Hein L. Presynaptic metabotropic receptors for acetylcholine and adrenaline/noradrenaline. Handb Exp Pharmacol 2008; 261-288
25 Gilsbach R, Albarran-Juarez J, Hein L. Pre- versus postsynaptic signaling by alpha(2)-adrenoceptors. Curr Top Membr 2011; 67: 139-160
26 Matsuo S, Jang IS, Nabekura J et al. alpha 2-Adrenoceptor-mediated presynaptic modulation of GABAergic transmission in mechanically dissociated rat ventrolateral preoptic neurons. J Neurophysiol 2003; 89: 1640-1648
27 Liu YW, Li J, Ye JH. Histamine regulates activities of neurons in the ventrolateral preoptic nucleus. J Physiol 2010; 588: 4103-4116
28 Mitchell HA, Weinshenker D. Good night and good luck: norepinephrine in sleep pharmacology. Biochem Pharmacol 2010; 79: 801-809
29 Kumar R. Approved and investigational uses of modafinil: an evidence-based review. Drugs 2008; 68: 1803-1839
30 Young JW, Geyer MA. Action of modafinil – increased motivation via the dopamine transporter inhibition and D1 receptors?. Biol Psychiatry 2010; 67: 784-787
31 Godfrey J. Safety of therapeutic methylphenidate in adults: a systematic review of the evidence. J Psychopharmacol 2009; 23: 194-205
32 Leonard BE, McCartan D, White J et al. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol 2004; 19: 151-180
33 Sullivan SS, Guilleminault C. Emerging drugs for insomnia: new frontiers for old and novel targets. Expert Opin Emerg Drugs 2009; 14: 411-422
34 Nowell PD, Mazumdar S, Buysse DJ et al. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 1997; 278: 2170-2177
35 Pandi-Perumal SR, Srinivasan V, Spence DW et al. Role of the melatonin system in the control of sleep: therapeutic implications. CNS Drugs 2007; 21: 995-1018
36 Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol 2005; 20: 533-559
37 Schmid DA, Wichniak A, Uhr M et al. Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology 2006; 31: 832-844
38 Croom KF, Perry CM, Plosker GL. Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs 2009; 23: 427-452
39 Arnsten AF, Scahill L, Findling RL. alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data. J Child Adolesc Psychopharmacol 2007; 17: 393-406
40 Miyazaki S, Uchida S, Mukai J et al. Clonidine effects on all-night human sleep: opposite action of low- and medium-dose clonidine on human NREM-REM sleep proportion. Psychiatry Clin Neurosci 2004; 58: 138-144
41 Philipsen A, Richter H, Schmahl C et al. Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. J Clin Psychiatry 2004; 65: 1414-1419
42 Garrett BN, Kaplan NM. Clonidine in the treatment of hypertension. J Cardiovasc Pharmacol 1980; 2 (Suppl. 01) S61-S71
43 Soyka M, Kranzler HR, van den Brink W et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence. World J Biol Psychiatry 2011; 12: 160-187
44 Onesti G, Bock KD, Heimsoth V et al. Clonidine: a new antihypertensive agent. Am J Cardiol 1971; 28: 74-83
45 Bohrer H, Bach A, Layer M et al. Clonidine as a sedative adjunct in intensive care. Intensive Care Med 1990; 16: 265-266
46 Huang YS, Tsai MH. Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge. CNS Drugs 2011; 25: 539-554
47 Conner CS, Watanabe AS. Clonidine overdose: a review. Am J Hosp Pharm 1979; 36: 906-911
48 Ernsberger P, Giuliano R, Willette RN et al. Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. J Pharmacol Exp Ther 1990; 253: 408-418
49 Bronstein AC, Spyker DA, Cantilena Jr LR et al. 2008; Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 26^th Annual Report. Clin Toxicol (Phila) 2009; 47: 911-1084
50 Scahill L. Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness. CNS Drugs 2009; 23 (Suppl. 01) 43-49
51 Spiegel R, DeVos JE. Central effects of guanfacine and clonidine during wakefulness and sleep in healthy subjects. Br J Clin Pharmacol 1980; 10 (Suppl. 01) 165S-168S
52 Arnsten AF, Cai JX, Goldman-Rakic PS. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. J Neurosci 1988; 8: 4287-4298
53 Jarrott B, Lewis SJ, Doyle AE et al. Effects of continuous infusions (10 days) and cessation of infusions of clonidine and rilmenidine (S 3341) on cardiovascular and behavioral parameters of spontaneously hypertensive rats. Am J Cardiol 1988; 61: 39D-44D
54 Reid JL, Campbell BC, Hamilton CA. Withdrawal reactions following cessation of central alpha-adrenergic receptor agonists. Hypertension 1984; 6: II71-II75
55 Geyskes GG, Boer P, Dorhout Mees EJ. Clonidine withdrawal. Mechanism and frequency of rebound hypertension. Br J Clin Pharmacol 1979; 7: 55-62
56 Pichot C, Ghignone M, Quintin L. Dexmedetomidine and clonidine: from second-to-first-line sedative agents in the critical care setting?. J Intensive Care Med 2011;
57 Hoobler SW, Kashima T. Central nervous system actions of clonidine in hypertension. Mayo Clin Proc 1977; 52: 395-398
58 Bonhomme V, Maquet P, Phillips C et al. The effect of clonidine infusion on distribution of regional cerebral blood flow in volunteers. Anesth Analg 2008; 106: 899-909 table of contents
59 Birnbaum SG, Podell DM, Arnsten AF. Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav 2000; 67: 397-403
60 Philipp M, Brede M, Hein L. Physiological significance of alpha(2)-adrenergic receptor subtype diversity: one receptor is not enough. Am J Physiol Regul Integr Comp Physiol 2002; 283: R287-R295
61 De Sarro GB, Ascioti C, Froio F et al. Evidence that locus coeruleus is the site where clonidine and drugs acting at alpha 1- and alpha 2-adrenoceptors affect sleep and arousal mechanisms. Br J Pharmacol 1987; 90: 675-685
62 Gentili A, Godschalk MF, Gheorghiu D et al. Effect of clonidine and yohimbine on sleep in healthy men: a double-blind, randomized, controlled trial. Eur J Clin Pharmacol 1996; 50: 463-465
63 Nelson LE, Lu J, Guo T et al. The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anesthesiology 2003; 98: 428-436
64 Ebert TJ, Hall JE, Barney JA et al. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology 2000; 93: 382-394
65 Venn RM, Bradshaw CJ, Spencer R et al. Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. Anaesthesia 1999; 54: 1136-1142
66 Uhlen S, Wikberg JE. Delineation of rat kidney alpha 2A- and alpha 2B-adrenoceptors with [³H]RX821002 radioligand binding: computer modelling reveals that guanfacine is an alpha 2A-selective compound. Eur J Pharmacol 1991; 202: 235-243
67 Sorkin EM, Heel RC. Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs 1986; 31: 301-336
68 Kiechel JR. Pharmacokinetics and metabolism of guanfacine in man: a review. Br J Clin Pharmacol 1980; 10 (Suppl. 01) 25S-32S
69 Cornish LA. Guanfacine hydrochloride: a centrally acting antihypertensive agent. Clin Pharm 1988; 7: 187-197
70 Kugler J, Seus R, Krauskopf R et al. Differences in psychic performance with guanfacine and clonidine in normotensive subjects. Br J Clin Pharmacol 1980; 10 (Suppl. 01) 71S-80S
71 Jakala P, Riekkinen M, Sirvio J et al. Guanfacine, but not clonidine, improves planning and working memory performance in humans. Neuropsychopharmacology 1999; 20: 460-470
72 Malanga G, Reiter RD, Garay E. Update on tizanidine for muscle spasticity and emerging indications. Expert Opin Pharmacother 2008; 9: 2209-2215
73 Henney 3rd HR, Runyan JD. A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients. Int J Clin Pract 2008; 62: 314-324
74 Spiller HA, Bosse GM, Adamson LA. Retrospective review of tizanidine (Zanaflex) overdose. J Toxicol Clin Toxicol 2004; 42: 593-596
75 Tanaka H, Fukuda I, Miyamoto A et al. Effects of tizanidine for refractory sleep disturbance in disabled children with spastic quadriplegia. No To Hattatsu 2004; 36: 455-460
76 Peskind ER, Bonner LT, Hoff DJ et al. Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder. J Geriatr Psychiatry Neurol 2003; 16: 165-171
77 McEvoy GK. ed. drug information 2005. Bethesda, MD: American Society of Health-System Pharmacists Inc; 2005: 1742-1746
78 Mallick BN, Alam MN. Different types of norepinephrinergic receptors are involved in preoptic area mediated independent modulation of sleep-wakefulness and body temperature. Brain Res 1992; 591: 8-19
79 Vetrivelan R, Mallick HN, Kumar VM. Tonic activity of alpha1 adrenergic receptors of the medial preoptic area contributes towards increased sleep in rats. Neuroscience 2006; 139: 1141-1151
80 Kumar VM, Vetrivelan R, Mallick HN. Alpha-1 adrenergic receptors in the medial preoptic area are involved in the induction of sleep. Neurochem Res 2006; 31: 1095-1102
81 Pellejero T, Monti JM, Baglietto J et al. Effects of methoxamine and alpha-adrenoceptor antagonists, prazosin and yohimbine, on the sleep-wake cycle of the rat. Sleep 1984; 7: 365-372
82 Larochelle P, du Souich P, Hamet P et al. Prazosin plasma concentration and blood pressure reduction. Hypertension 1982; 4: 93-101
83 Andros E, Detmar-Hanna D, Suteparuk S et al. The effect of aging on the pharmacokinetics and pharmacodynamics of prazosin. Eur J Clin Pharmacol 1996; 50: 41-46
84 Jaillon P. Clinical pharmacokinetics of prazosin. Clin Pharmacokinet 1980; 5: 365-376
85 Lund-Johansen P, Hjermann I, Iversen BM et al. Selective alpha-1 inhibitors: first- or second-line antihypertensive agents?. Cardiology 1993; 83: 150-159
86 Melkild A. Prazosin (‘Peripress’): a long-term study. Curr Med Res Opin 1984; 9: 219-228
87 Raskind MA, Peskind ER, Kanter ED et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry 2003; 160: 371-373
88 Raskind MA, Peskind ER, Hoff DJ et al. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry 2007; 61: 928-934
89 McGough JJ, Barkley RA. Diagnostic controversies in adult attention deficit hyperactivity disorder. Am J Psychiatry 2004; 161: 1948-1956
90 Philipsen A, Hesslinger B, Tebartz van Elst L. Attention deficit hyperactivity disorder in adulthood: diagnosis, etiology and therapy. Dtsch Arztebl Int 2008; 105: 311-317
91 Polanczyk G, de Lima MS, Horta BL et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007; 164: 942-948
92 Brown RT, Amler RW, Freeman WS et al. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics 2005; 115: e749-e757
93 Turner D. A review of the use of modafinil for attention-deficit hyperactivity disorder. Expert Rev Neurother 2006; 6: 455-468
94 Prince JB, Wilens TE, Biederman J et al. Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder: a systematic chart review of 62 cases. J Am Acad Child Adolesc Psychiatry 1996; 35: 599-605
95 Scahill L, Chappell PB, Kim YS et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001; 158: 1067-1074
96 Spencer TJ, Greenbaum M, Ginsberg LD et al. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009; 19: 501-510
97 Sallee FR, Lyne A, Wigal T et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009; 19: 215-226
98 Palumbo DR, Sallee FR, Pelham Jr WE et al. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry 2008; 47: 180-188
99 Kessler RC, Berglund P, Demler O et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593-602
100 Ulmer CS, Edinger JD, Calhoun PS. A multi-component cognitive-behavioral intervention for sleep disturbance in veterans with PTSD: a pilot study. J Clin Sleep Med 2011; 7: 57-68
101 Seal KH, Maguen S, Cohen B et al. VA mental health services utilization in Iraq and Afghanistan veterans in the first year of receiving new mental health diagnoses. J Trauma Stress 2010; 23: 5-16
102 Saul AL, Grant KE, Carter JS. Post-traumatic reactions in adolescents: how well do the DSM-IV PTSD criteria fit the real life experience of trauma exposed youth?. J Abnorm Child Psychol 2008; 36: 915-925
103 Maher MJ, Rego SA, Asnis GM. Sleep disturbances in patients with post-traumatic stress disorder: epidemiology, impact and approaches to management. CNS Drugs 2006; 20: 567-590
104 Mellman TA, Kulick-Bell R, Ashlock LE et al. Sleep events among veterans with combat-related posttraumatic stress disorder. Am J Psychiatry 1995; 152: 110-115
105 Arnsten AF, Mathew R, Ubriani R et al. Alpha-1 noradrenergic receptor stimulation impairs prefrontal cortical cognitive function. Biol Psychiatry 1999; 45: 26-31
106 Taylor FB, Martin P, Thompson C et al. Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry 2008; 63: 629-632
107 Berger W, Mendlowicz MV, Marques-Portella C et al. Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a systematic review. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 169-180
108 Byers MG, Allison KM, Wendel CS et al. Prazosin versus quetiapine for nighttime posttraumatic stress disorder symptoms in veterans: an assessment of long-term comparative effectiveness and safety. J Clin Psychopharmacol 2010; 30: 225-229
109 Friedman MJ. Toward rational pharmacotherapy for posttraumatic stress disorder: an interim report. Am J Psychiatry 1988; 145: 281-285
110 Boehnlein JK, Kinzie JD. Pharmacologic reduction of CNS noradrenergic activity in PTSD: the case for clonidine and prazosin. J Psychiatr Pract 2007; 13: 72-78
111 Ziegenhorn AA, Roepke S, Schommer NC et al. Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2009; 29: 170-173
112 Dahmani S, Brasher C, Stany I et al. Premedication with clonidine is superior to benzodiazepines. A meta analysis of published studies. Acta Anaesthesiol Scand 2010; 54: 397-402
113 Stuhmeier KD, Mainzer B, Cierpka J et al. Small, oral dose of clonidine reduces the incidence of intraoperative myocardial ischemia in patients having vascular surgery. Anesthesiology 1996; 85: 706-712
114 Arain SR, Ebert TJ. The efficacy, side effects, and recovery characteristics of dexmedetomidine versus propofol when used for intraoperative sedation. Anesth Analg 2002; 95: 461-466 table of contents
115 Szumita PM, Baroletti SA, Anger KE et al. Sedation and analgesia in the intensive care unit: evaluating the role of dexmedetomidine. Am J Health Syst Pharm 2007; 64: 37-44
116 Cohen DJ, Young JG, Nathanson JA et al. Clonidine in Tourette’s syndrome. Lancet 1979; 2: 551-553
117 Leckman JF, Hardin MT, Riddle MA et al. Clonidine treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry 1991; 48: 324-328
118 Goetz CG, Tanner CM, Wilson RS et al. Clonidine and Gilles de la Tourette’s syndrome: double-blind study using objective rating methods. Ann Neurol 1987; 21: 307-310
119 Tourette’s Syndrome Study Group . Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002; 58: 527-536
120 Bloch MH, Panza KE, Landeros-Weisenberger A et al. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 2009; 48: 884-893
121 Trenkwalder C, Paulus W. Restless legs syndrome: pathophysiology, clinical presentation and management. Nat Rev Neurol 2010; 6: 337-346
122 Berger K, Kurth T. RLS epidemiology – frequencies, risk factors and methods in population studies. Mov Disord 2007; 22 (Suppl. 18) S420-S423
123 Trenkwalder C, Benes H, Poewe W et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008; 7: 595-604
124 Wagner ML, Walters AS, Coleman RG et al. Randomized, double-blind, placebo-controlled study of clonidine in restless legs syndrome. Sleep 1996; 19: 52-58
125 Itskovitz HD, Krug K, Khoury S et al. The long-term antihypertensive effects of prazosin and atenolol. Am J Med 1989; 86: 82-86
126 Ferder L, Inserra F, Medina F. Safety aspects of long-term antihypertensive therapy (10 years) with clonidine. J Cardiovasc Pharmacol 1987; 10 (Suppl. 12) S104-S108
127 Khatri IM, Levinson P, Notargiacomo A et al. Initial and long-term effects of prazosin on sympathetic vasopressor responses in essential hypertension. Am J Cardiol 1985; 55: 1015-1018
128 Riemann D, Spiegelhalder K, Feige B et al. The hyperarousal model of insomnia: a review of the concept and its evidence. Sleep Med Rev 2010; 14: 19-31